Arix Bioscience PLC (ARIX)
Unaudited NAV for November 2022
12-Dec-2022 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Arix Bioscience plc
Unaudited NAV for November 2022
LONDON, 12 December 2022:Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value (“NAV”) of the Company for the date ended 30 November 2022 as follows:
Date |
NAV Breakdown |
Total NAV |
NAV per share |
|||
Listed Portfolio |
Unlisted Portfolio |
Cash |
Other Interests |
|||
|
30 November 22 (unaudited) |
£41.8m |
£57.1m |
£130.0m |
£1.9m |
£230.8m |
£1.79 |
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
Powerscourt Group
Sarah MacLeod,Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
| ISIN: | GB00BD045071 |
| Category Code: | NAV |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| Sequence No.: | 207309 |
| EQS News ID: | 1508581 |
| End of Announcement | EQS News Service |
==